ADC (Antibody-Drug Conjugate) development and CMO beneficiaries
For reference only. Not investment advice. You are solely responsible for your investment decisions.
6/24 · Real-time
No losers
Of 6 ADC Antibody-Drug Conjugate stocks tracked today, 6 are up and 0 down (avg +4.25%), an overall strongly higher tone. The top gainer is 알테오젠 (+7.21%), while SK바이오팜 (+2.55%) lags the group.
Based on live prices and updated periodically. Not investment advice.
ADC (Antibody-Drug Conjugate) development and CMO beneficiaries Switch between Korean and US stock tabs below to see live prices.
Based on publicly known business structure. Not investment advice.
ADC Antibody-Drug Conjugate Stocks is a key investment theme in 2026. ADC (Antibody-Drug Conjugate) development and CMO beneficiaries PFlow tracks 14 related stocks — 7 Korean and 7 US — with live prices in one view.
There are 14 stocks related to ADC Antibody-Drug Conjugate Stocks — 7 Korean and 7 US stocks. Check live prices and performance in the tabs above.
PFlow's ADC Antibody-Drug Conjugate Stocks page (pflow.app/en/theme/adc) shows Korean and US leading stocks with live price changes. Click any stock to view detailed data.
Korean ADC Antibody-Drug Conjugate Stocks stocks are 7 KOSPI/KOSDAQ-listed companies, while US ADC Antibody-Drug Conjugate Stocks stocks are 7 NASDAQ/NYSE-listed companies. Comparing both helps gauge global demand trends and valuation differences.
There are 14 companies related to ADC Antibody-Drug Conjugate — 7 Korean and 7 US. Check their live prices and leading stocks in the list above.
※ This page provides price information for companies with business connections to the listed theme. It is not a recommendation to buy or sell any specific stock. Investors are solely responsible for their investment decisions. Please conduct thorough research before investing.